LDC and UGISense AG to Collaborate on New Drug Class
Lead Discovery Center GmbH (LDC) and the biotech company UGISense AG are about to initiate a collaboration to jointly develop innovative drugs using the proprietary UgimeresTM antisense platform.
LDC Teams up with Canadian McGill University in $1 Million Translational Drug Discovery Project
First research project to be funded under the Canada/Germany Program
Researchers from the Lead Discovery Center (LDC) in Dortmund, Germany led by Dr. Bert Klebl and McGill University in Montréal, Canada led by Dr. David Y. Thomas will work closely together to identify novel tools for protein trafficking and folding diseases drug discovery.The 3-years research initiative between LDCand McGill University will be funded for a total of $1M.
LDC and Boehringer Ingelheim Join Forces to Discover a Novel Approach for the Treatment of Schizophrenia
The Lead Discovery Center GmbH (LDC), Max Planck Innovation GmbH and Boehringer Ingelheim International GmbH have signed an agreement providing Boehringer Ingelheim with the option to receive the exclusive rights to a new lead compound for the treatment of schizophrenia to be discovered and developed at the LDC.
LDC Enters new Industry Partnership for the Discovery of Novel Medicines
LDC and Roche will jointly advance innovative drug discovery projects
The Lead Discovery Center GmbH (LDC) and Roche will collaborate to identify and leverage innovative therapeutic opportunities that address diseases of unmet medical need across several disease areas.
LDC and Infinity Pharmaceuticals to Cooperate on the Identification of Novel Drug Discovery and Development Opportunities in Oncology
LDC and Infinity Pharmaceuticals, Inc. – Cambridge, MA – will work together to jointly select high-potential cancer drug discovery projects from the LDC’s portfolio and its broad academic network.
LDC to Collaborate with Johnson & Johnson Innovation on Acceleration of Academic Drug Discovery Initiatives
LDC and Johnson & Johnson Innovation Ltd., will collaborate to identify and accelerate innovative drug candidates for the treatment and prevention of diseases with high unmet medical needs.
LDC and Qurient Close Licence Agreement on Novel Anti-cancer Compound
LDC and Qurient Co., Ltd have signed a licence deal providing Qurient with exclusive worldwide rights to a series of highly-selective CDK7 inhibitors discovered at the LDC for the treatment of cancer, inflammation and viral infections. The partners will closely collaborate to advance the approach from the validated lead stage into clinical development. Upon successful proof-of-concept in humans they will jointly identify a suitable partner for follow-on licensing.
The Charcot-Marie-Tooth Association enters collaboration with LDC’s subsidiary Affectis to advance therapies for Charcot-Marie-Tooth 1A disorder
The Charcot-Marie-Tooth Association (CMTA) announced today that it has entered into a collaboration with Affectis Pharmaceuticals AG to evaluate the efficacy of advanced Affectis compounds in neurological and behavioral models of CMT1A.
Affectis is a therapy development company and since 2013 a fully owned subsidiary of LDC. The small molecule antagonists of the P2X7 ligand-gated ion channel are being jointly developed by Affectis and the LDC.
LDC and AstraZeneca broaden Drug Discovery Alliance
The Lead Discovery Center GmbH (LDC) and AstraZeneca have expanded their alliance to discover new medicines for the treatment of human diseases with high unmet medical need. Through an additional three-year period of collaboration, AstraZeneca will provide an extended set of high-quality compounds to the LDC’s internal screening collection to pursue projects in the areas of cardiovascular and metabolic diseases, oncology, respiratory and inflammation and neuroscience.
LDC and HZI enter partnership for the discovery of new drugs against multi-resistant bacteria
The Lead Discovery Center GmbH (LDC) and the Helmholtz Centre for Infection Research (HZI) will be working in close cooperation to identify and optimize new drug candidates against methicillin-resistant Staphylococcus aureus (MRSA).
Nature’s pharmacy – plant-based active substance kills renal cancer cells
Collaboration with the LDC to explore the development of a Englerin-A inspired cancer drug
Nature holds many compounds in store that are of great value to medical research. Recently, for example, scientists discovered that a substance contained in an African shrub kills cancer cells in the kidney. Together with colleagues from Berlin and Leeds, researchers from the Max Planck Institute of Molecular Physiology in Dortmund discovered that the molecule known as englerin A significantly increases the concentration of calcium in cells, causing the cancer cells to die. Englerin A only activates the calcium channels of renal cancer cells, but not those of healthy cells. In cooperation with the Lead Discovery Center in Dortmund, the scientists now want to find out whether englerin A could potentially be used as an innovative drug to treat renal cancer in the future.
LDC Receives 1 Million Euros from the Max Planck Foundation for the Development of New Drug Candidates
The Lead Discovery Center (LDC) receives two grants of EUR 0.5 Million each for the development of two innovative drug discovery approaches for treating inflammation and cancer. The funds originate half-and-half from the Max Planck Foundation (MPF) and the Dr Helmut Storz Foundation, which is managed by the MPF.
news & press
Response to the structural transformation of the pharma industry [German only]
Bert Klebl, Peter Nussbaumer and Matthias Stein-Gerlach; transkript | Special Issue Kapital & Börse May 2009
Polishing Medical Rough Diamonds
Text: Marcus Anhäuser
Max Planck Society Magazine Special “Innovation” / 2009
Pages 47 – 53
Joint Initiative for Research and Innovation